Efficacy of risankizumab versus ustekinumab by baseline Crohn’s Disease location: post-hoc analysis of the SEQUENCE head-to-head trialECCO'24 Stockholm 2024
Endoscopic healing in paediatric IBD perpetuates a persistent signature characterized by pathogenic Th17 cells and tissue-associated molecular and microbial drivers of diseaseECCO'24 Stockholm 2024
Endoscopy - visualisation of disease activity, modern disease characterisationECCO'24 Stockholm 2024
Endothelial cell-mediated smooth muscle hyperplasia in Crohn’s disease intestinal strictures: Caveolin 1 as a potential therapeutic targetECCO'24 Stockholm 2024
Exploring the potential clinical utility of NUDT15 pharmacogenetic testing in clinical practice: a ‘focused reverse phenotyping’ study in the UK IBD BioresourceECCO'24 Stockholm 2024
Faecal microbiota transplantation in active Ulcerative Colitis: Key lessons from a randomized controlled trial halted for futilityECCO'24 Stockholm 2024
Fibrosis-related transcriptome unveils a distinctive matrix remodelling pattern in penetrating but not in stricturing ileal Crohn's DiseaseECCO'24 Stockholm 2024
FOod Additives on the Mucosal barrier study (FOAM): Effect of five emulsifiers on inflammation, intestinal permeability, and the microbiome: preliminary results.ECCO'24 Stockholm 2024
Frequency and effectiveness of dose escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDAECCO'24 Stockholm 2024
Gaps between ECCO quality standards of care and the real world: the E-QUALITY survey on processes and outcomesECCO'24 Stockholm 2024
Gene correlation network analyses reveal transcript modules and pathogenic mechanisms associated with resistance and response to ustekinumab therapy in Ulcerative ColitisECCO'24 Stockholm 2024
Guselkumab and golimumab combination induction therapy in Ulcerative Colitis results in early local tissue healing that is sustained through guselkumab maintenance therapyECCO'24 Stockholm 2024
Guselkumab improves health-related quality of life as measured by PROMIS-29 in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction studyECCO'24 Stockholm 2024
Guselkumab improves symptoms of fatigue in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction study results at Week 12ECCO'24 Stockholm 2024
Guselkumab induction restores intestinal immune homeostasis and promotes epithelial repair in moderately to severely active Ulcerative ColitisECCO'24 Stockholm 2024